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bjectives We sought to evaluate at 5 years the occurrence of cardiac death; cardiac death, and/or
yocardial infarction (MI); cardiac death, MI, and/or stroke; target vessel revascularization; and major
dverse cardiac and cerebrovascular events following percutaneous coronary intervention (PCI) with
rug-eluting stent (DES) versus coronary artery bypass graft (CABG) in unprotected left main coro-
ary artery lesions.
ackground Preliminary results at 1 year showed comparable occurrence of major adverse cardiac
nd cerebrovascular events in our center between PCI and CABG.
ethods All consecutive patients with an unprotected left main coronary artery stenosis elec-
ively treated with DES implantation versus CABG in our center, between March 2002 and July
004, were analyzed. A propensity analysis was performed to adjust for baseline differences be-
ween the 2 cohorts.
esults We included 249 patients in the study: 107 were treated with PCI and DES implantation
nd 142 with CABG. At 5-year clinical follow-up, no difference was found between PCI and CABG in
he occurrence of cardiac death (adjusted odds ratio [OR]: 0.502; 95% conﬁdence interval [CI]: 0.162
o 1.461; p  0.24). The PCI group showed a trend toward a lower occurrence of the composite end
oint of cardiac death and MI (adjusted OR: 0.408; 95% CI: 0.146 to 1.061; p  0.06). Percutaneous
oronary intervention was associated with a lower rate of the composite end point of death, MI,
nd/or stroke (OR: 0.399; 95% CI: 0.151 to 0.989; p  0.04). Indeed, CABG was correlated with lower
arget vessel revascularization (adjusted OR: 4.411; 95% CI: 1.825 to 11.371; p  0.0004). No differ-
nce was detected in the occurrence of major adverse cardiac and cerebrovascular events (adjusted
R: 1.578; 95% CI: 0.825 to 3.054; p  0.18).
onclusions At 5-year clinical follow-up, there was still no difference in the occurrence of major
dverse cardiac and cerebrovascular events between elective PCI with DES implantation and CABG
n unprotected left main coronary artery lesions in this single-center experience. There was an ad-
antage of PCI in the composite end point of death, MI, and/or stroke, whereas a beneﬁt in the
eed for reintervention was still found in CABG. (J Am Coll Cardiol Intv 2010;3:595–601) © 2010 by
he American College of Cardiology Foundation
rom the *Interventional Cardiology and Cardiac Surgery Units, Department of Cardio-Thoracic and Vascular Diseases,
an Raffaele Scientific Institute; and the †Emodinamica Gruppo Villa Maria (EMO GVM) Centro Cuore Columbus, Milan, Italy.anuscript received March 5, 2010, accepted March 18, 2010.
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DES Versus CABG in ULMCA at 5 Years
596ccording to current guidelines, the treatment of unpro-
ected left main coronary artery (ULMCA) disease with
ercutaneous coronary intervention (PCI) has a Class IIb
ndication (1). Registry data of PCI with drug-eluting stent
DES) implantation in ULMCA lesions have shown that
his is a feasible and safe approach, at mid-term clinical
ollow-up (2–11). Recently, results from multicenter regis-
ries have reported favorable outcomes at up to 3-year
linical follow-up (12–14). Moreover, registries evaluating
CI with DES versus coronary artery bypass graft (CABG)
See page 642
n this subset of patients have reported encouraging results.
he randomized SYNTAX (Synergy between Percutaneous
Coronary Intervention with Taxus
and Cardiac Surgery) study also
reported noninferiority in 12-
month major adverse cardiac and
cerebrovascular events (MACCE)
of PCI as compared with CABG
in this subset of patients (15).
We have previously reported no
difference in the degree of protec-
tion against death, stroke, myo-
cardial infarction (MI), and revas-
cularization between PCI with
DES and CABG for ULMCA
at 1 year (16). The aim of the
present study is to report 5-year
clinical follow-up of the treat-
ment of ULMCA stenosis with
PCI and DES implantation ver-
sus surgical revascularization.
Methods
All patients with ULMCA ste-
osis treated with PCI and DES implantation or CABG
etween March 2002 and July 2004 were analyzed. The
ecision to perform PCI or CABG depended on patient
omorbidities and/or physician’s choice. In all cases, the
evascularization approach selected appeared suitable to
uarantee complete revascularization. In general, if the
atient had a contraindication to 1-year dual antiplatelet
herapy (DAT) after PCI, then the patient was referred for
ABG. Hierarchical study end points were the composite
ccurrence at 5 years of cardiac death; cardiac death or MI;
ardiac death, MI, or stroke; repeat revascularization; car-
iac death, MI, stroke, or repeat revascularization. Clinical
ollow-up was scheduled and obtained for all patients at 60
bbreviations
nd Acronyms
ABG  coronary artery
ypass graft
VA  cerebrovascular
ccident
AT  dual antiplatelet
herapy
ES  drug-eluting stent(s)
ACCE  major adverse
ardiac and cerebrovascular
vents
I  myocardial infarction
CI  percutaneous
oronary intervention
T  stent thrombosis
LR  target lesion
evascularization
VR  target vessel
evascularization
LMCA  unprotected left
ain coronary arteryonths. tIn patients treated with PCI, DAT (i.e., aspirin 100
g daily and clopidogrel 75 mg daily or ticlopidine 250
g twice daily) was administrated for at least 12 months.
etailed information on adherence as well as reasons and
ate for discontinuation of DAT was obtained in all
atients. Angiographic follow-up was scheduled if non-
nvasive evaluation or clinical presentation suggested
schemia.
eﬁnitions. Definition of hospital non–Q-wave MI was
llustrated in the previous report (16).
In this report, the following MACCE were analyzed
umulatively at 5-year clinical follow-up: cardiac death, MI,
erebrovascular events, target lesion revascularization
TLR), and target vessel revascularization (TVR). The
ccurrence of stent thrombosis (ST) was defined on the
asis of the Academic Research Consortium definitions (17)
n the PCI group; whereas the occurrence of symptomatic
raft occlusion was evaluated in the CABG group (15).
eaths were classified as either cardiac or noncardiac.
ardiac death was defined as any death due to a cardiac
ause (e.g., MI, low-output failure, fatal arrhythmia),
rocedure-related deaths, and death of unknown cause. We
efined TLR as any revascularization performed on the
reated segment and TVR as any revascularization per-
ormed on the treated vessel considering also treatment of
ny segment in left anterior descending and circumflex
rtery. Cerebrovascular accident (CVA) was defined as
troke, transient ischemic attacks, and reversible ischemic
eurological deficits adjudicated by a neurologist and con-
rmed by computed tomography scanning (15).
In this analysis, the following were included as cumulative
I: 1) all Q-wave MIs that occurred during hospital stay
nd at follow-up; and 2) all spontaneous MIs occurring after
ospital discharge.
Q-wave MI was defined as the development of new
athological Q waves in 2 or more contiguous leads (ac-
ording to the Minnesota Code as assessed by the electro-
ardiogram core laboratory) with or without creatine kinase
r creatine kinase-myocardial band levels elevated above
ormal.
“Spontaneous” MI was defined as the occurrence after
ospital discharge of any value of troponin and/or creatine
inase-myocardial band greater than the upper limit of
ormal if associated with clinical and/or electrocardio-
raphic change.
The EuroSCORE (European System for Cardiac Operative
isk Evaluation), which is based on patient-, cardiac-, and
peration-related factors, was used to stratify the risk of death
t 30 days. According to the scoring system, the patients were
tratified as high risk in the presence of a EuroSCORE 6
nd as very high risk if EuroSCORE was 13.
tatistical analysis. Data are presented as percentages and
ean  SD. In general, differences in proportions wereested with chi-square test or Fisher exact test, and differ-
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597nces in location parameters of continuous variables were
ested with a Student t test. Because of the nonrandomized
ature of the study, a propensity score analysis was per-
ormed to minimize any selection bias due to the differences
n clinical characteristics between the 2 treatment groups.
riefly, for each patient, a propensity score, indicating the
ikelihood of having PCI, was calculated by the use of a
ultivariable logistic regression that identifies variables
ndependently associated with PCI. Variables included in
he logistic regression analysis were age, sex, diabetes, hyper-
ension, hypercholesterolemia, smoking, familiar history of
oronary artery disease, unstable angina, renal failure, left
entricular ejection fraction, EuroSCORE, EuroSCORE6,
ight coronary artery disease, and right coronary artery treat-
ent during the index procedure. The C statistic for the
ropensity score model was 0.78, indicating a good discrimi-
ation. Patients were subsequently divided into 4 subgroups
ccording to the quartiles of the propensity score. The impact
f PCI on cardiac death; cardiac death or MI; cardiac death,
I, or stroke; repeat revascularization and MACCE during
ospital stay; and at 5-year follow-up was investigated in all 4
ubgroups of patients with similar characteristics, between PCI
nd CABG. Exact logistic regression models based on permu-
ation resampling were employed to perform unadjusted uni-
ariate analyses, stratified analyses using the propensity score
uartiles as variable, and the subgroup analyses performed
ithin each propensity score quartile. Results were reported as
dds ratios (ORs) together with associated exact 95% confi-
ence intervals (CIs). The SAS version 9.1 (SAS Institute,
ary, North Carolina) was used for the analysis.
esults
aseline clinical characteristics are summarized in Table 1.
A total of 249 patients were treated: 142 with CABG and
07 with PCI and DES implantation. In the PCI group, 52
atients had paclitaxel- and 55 sirolimus-eluting stent
mplantation. Patients treated with PCI were younger
63.6  10.3 years vs. 67.5  9.7 years; p  0.002), less
requently had hypertension (58.8% vs. 76.0%; p  0.006)
nd renal failure (1.9% vs. 8.4%; p  0.02), but more often
resented with unstable angina (31.8% vs. 21.8%; p 0.08).
iabetes mellitus was present in 20 (18.7%) patients of the
CI group and 33 (23.2%) of the CABG group (p  0.44).
o patient included in this study had a malignancy at the
ime of the procedure. More patients treated with CABG
ad additional disease in the right coronary artery (69.0% vs.
0.4%); this was treated during the index procedure in
8.3% versus 16.9% of the patients, respectively (p 0.0001
or both comparisons). All other variables were similar.
ighty-seven (81.3%) patients treated with PCI had distal
LMCA stenosis: 77 were bifurcations and 10 trifurca-
ions. Both branches were stented in most of the patients
73.6%), probably reflecting the complexity of bifurcation 5reated and our bifurcation stenting strategy at the time of
he report. No differences were observed in SYNTAX scores
etween the 2 study groups.
In-hospital and 1-year outcome have been previously
eported (16). Table 2 illustrates the occurrence of MACCE
n-hospital and at 1 and 5 years. At a median follow-up time
f 61.9 months (interquartile range [IQR]: 57.8 to 67.2
onths), 26 patients (18.3%) in the CABG versus 17
atients (15.9%) in the PCI group died. Among them, 17
11.9%) were adjudicated as cardiac death in the CABG
ohort and 8 (7.5%) in the PCI group. Eleven patients
7.7%) in the CABG arm experienced a MI whereas only 1
atient (0.9%) did in the PCI group. Target lesion revas-
ularization was performed in 12 (8.4%) versus 20 patients
18.7%) in the CABG and PCI groups, respectively. Twelve
atients (8.4%) in the CABG group and 30 patients (28%)
n the PCI arm underwent a TVR. Among the 30 patients
n the PCI group, only 6 underwent a surgical revascular-
zation. Cerebrovascular accident occurred in 6 patients
4.2%) in the CABG group and in only 1 patient (0.9%) in
he PCI group.
Symptomatic graft occlusion occurred in 4 patients
2.8%) treated with CABG; definite and/or probable ST
as adjudicated in 0.93% of patients that underwent PCI
only 1 definite ST and no probable ST). The only definite
T was a late ST in a paclitaxel-eluting stent implanted in
he proximal left anterior descending artery at 3.9 months
hile on DAT. The patient experienced an anterior acute
I successfully treated with repeat PCI. Possible ST at
Table 1. Clinical Characteristics of the Patients Treated With
PCI Versus CABG
PCI
(n  107)
CABG
(n  142) p Value
Age, yrs 63.6 10.3 67.5 9.7 0.0026
Diabetes mellitus 20 (18.7%) 33 (23.2%) 0.44
Smokers 53 (49.5%) 84 (59.1%) 0.16
Hypertension 63 (58.8%) 108 (76.0%) 0.006
Hypercholesterolemia 75 (70.0%) 98 (69.0%) 0.89
EuroSCORE 4.4 3.6 4.3 3.4 0.85
EuroSCORE 6 34 (31.7%) 41 (28.8%) 0.67
Renal failure 2 (1.9%) 12 (8.4%) 0.02
Disease in RCA 42 (40.4%) 98 (69.0%) 0.0001
RCA treatment 18 (16.9%) 68 (48.3%) 0.0001
LVEF, % 52.0 10.4 52.2 11.4 0.91
Unstable angina 34 (31.8%) 31 (21.8%) 0.08
SYNTAX score 28.8 10.4 29.4 5.78* 0.90
Data presented as n (%) or mean SD unless otherwise noted. *The SYNTAX (Synergy between
Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) study scores were calcu-
lated in 80 of 142 CABG patients.
CABG  coronary artery bypass graft; EuroSCORE  European System for Cardiac Operative
Risk Evaluation; LVEF left ventricular ejection fraction; PCI percutaneous coronary interven-
tion; RCA right coronary artery.-year follow-up was adjudicated in 6 patients (5.6%).
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598aseline characteristics of the patients with a possible ST
re illustrated in Table 3.
Notably, only 34% of the patients in PCI and 2% in
ABG groups were on long-term DAT at the time of last
linical follow-up. Regarding the adherence to any anti-
latelet therapy (aspirin or clopidogrel/ticlopidine), 12
8.4%) patients in CABG and 8 (7.4%) in PCI groups were
ot on any antiplatelet therapy at the time of last clinical
ontact.
Interestingly, no patient treated with PCI for ostial
nd/or shaft lesion died of cardiac cause or had an MI or a
VA during follow-up; only 1 patient had a TLR.
Table 2. Occurrence of MACCE In-Hospital and at 1 and 5 Years
Time of MACCE
CABG
(n  142)
DES
(n  107)
In-hospital, n (%)
Death 3 (2.1) 0
Cardiac death 2 (1.4) 0
MI 37 (26.0) 10 (9.3)
QW-MI 5 (3.5) 0
TVR 3 (2.1) 0
TLR 3 (2.1) 0
CVA 2 (1.4) 0
1 year, n (%)
Death 12 (8.1) 3 (2.8)
Cardiac death 7 (4.9) 2 (1.8)
MI 7 (4.9) 1 (0.9)
TVR 8 (5.6) 21 (19.6)
TLR 8 (5.6) 17 (15.8)
CVA 3 (2.1) 1 (0.9)
5 years, n (%)
Death 26 (18.3) 17 (15.9)
Cardiac death 17 (11.9) 8 (7.5)
MI 11 (7.7) 1 (0.9)
TVR 12 (8.4) 30 (28.0)
TLR 12 (8.4) 20 (18.7)
CVA 6 (4.2) 1 (0.9)
CVA cerebrovascular accidents; DES drug-eluting stent(s); MACCEmajor adverse cardiac
and cerebrovascular event; MI  myocardial infarction; QW  Q-wave; TLR  target lesion
revascularization; TVR target vessel revascularization; other abbreviations as in Table 1.
Table 3. Clinical Characteristics of the Patients Who Underwent Possible S
Patients EuroSCORE
SYNTAX
Score Age, yrs LVEF, %
Dis
Loca
1 13 45.0 83 28 Y
2 11 53.5 77 20 Y
3 5 25.0 60 35 Y
4 4 33.0 69 65 Y
5 7 45.5 73 35 Y
6 4 35.0 62 50 Y
DATdual antiplatelet therapy at the timeof possible ST; LVEF left ventricular ejection fraction; PEas in Table 1.tudy end points. At a median of 61.9 months (IQR: 57.8
o 67.2 months), no difference in cardiac death was observed
11.9% in CABG vs. 7.5% in PCI; unadjusted OR: 0.59;
5% CI: 0.21 to 1.5; p 0.34; adjusted OR: 0.502; 95% CI:
.16 to 1.46; p  0.24). No significant difference was also
ound, despite the presence of a trend in favor of PCI, in the
omposite end point of cardiac death and MI (16.9% in
ABG vs. 8.4% in PCI; unadjusted OR: 0.41; 95% CI: 0.16
o 0.95; p  0.04; adjusted OR: 0.408; 95% CI: 0.14 to
.06; p 0.06). A potential benefit of PCI over CABG was
uggested (confirming 1-year results) (16) in the composite
nd points of cardiac death, MI, and cerebrovascular events
20.4% in the CABG group vs. 11.2% in the PCI group;
nadjusted OR: 0.38; 95% CI: 0.16 to 0.86; p  0.02;
djusted OR: 0.43; 95% CI: 0.17 to 0.97; p 0.04) (Fig. 1).
onversely, there was a potential advantage of CABG in
he occurrence of TVR (8.4% vs. 28.0%, respectively) at
oth unadjusted (OR: 4.19; 95% CI: 1.9 to 9.6; p 0.0001)
nd adjusted analysis (OR: 4.41; 95% CI: 1.82 to 11.3; p 
.0004).
No difference in the occurrence of MACCE was observed
n PCI versus CABG (32.4% vs. 38.3%, respectively) both
or the unadjusted (OR: 1.41; 95% CI: 0.79 to 2.51; p 
.26) and adjusted analysis (OR: 1.57; 95% CI: 0.82 to 3.05;
 0.18) (Fig. 2).
iscussion
he main findings of this single-center study are: 1) there
as still no difference at a median of 61.9 months (IQR:
7.8 to 67.2 months) in the occurrence of MACCE
etween elective PCI with DES implantation and CABG
or ULMCA disease; 2) the benefit of PCI in the composite
nd point of cardiac death, MI, and cerebrovascular events
hat we reported at 1 year was still present at a longer term
linical follow-up; and 3) the advantage of CABG was
onfirmed in the lower need for repeated revascularization.
ccording to current guidelines, the treatment of ULMCA
isease with PCI has a Class IIb indication (1). Some
etrospective studies evaluating surgical treatment for this
isease reported an in-hospital mortality rate varying from
Stent Type Stenting Technique
Time of the Event,
Months
DAT at
Event
SES Crush 8.1 No
PES Crush 14.8 No
SES V-stenting 32.9 Yes
PES Crush 31.7 No
SES Provisional 46.3 Yes
PES Culotte 62.2 Yes
clitaxel-eluting stent(s); SES sirolimus-eluting stent(s); ST stent thrombosis; other abbreviationsT
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599.7% to 7.0% and a 1-year mortality rate of 6% to 14%
18–21).
Encouraging 1-year and more recently 3-year results have
een reported for PCI with DES implantation in this
articular subset of patients (2–11). Observational, nonran-
omized registries (5,13,16) reported thus far have shown
o difference in the occurrence of MACCE between pa-
ients treated with DES compared with the ones treated
ith CABG in this subset of patients. The most important
imitations of these registries were the different baseline
linical characteristics of the 2 populations (PCI and
ABG) adjusted with propensity score analysis and the
uration of follow-up.
More recently Seung et al. (22) in the MAIN COMPARE
Revascularization for Unprotected Left Main Coronary Ar-
ery Stenosis: Comparison of Percutaneous Coronary Angio-
lasty versus Surgical Revascularization) registry reported the
utcomes in 1,102 patients treated with PCI at a median
ollow-up of 1,017 days (IQR: 688 to 1,45 days) compared
ith the outcomes in 1,138 patients undergoing CABG at
,152 days (IQR: 681 to 1,590 days) of follow-up. In the
ropensity-matched cohort, there was no significant difference
etween the 2 revascularization strategies in the risk of death
hazard ratio [HR] for the stenting group: 1.18; 95% CI: 0.77
o 1.80) or the risk of the composite outcome (HR for the
Figure 1. Composite End Point of Cardiac Death, MI, and CVA at 5 Years
The ﬁgure shows the advantage of percutaneous coronary intervention
(PCI) with drug-eluting stent implantation as compared with coronary
artery bypass graft (CABG) in the composite end point of cardiac death,
myocardial infarction (MI), and cerebrovascular accidents (CVA) at 5-year
clinical follow-up. This advantage was present in the overall population and
according to quartiles at propensity score analysis. CI  conﬁdence
interval.tenting group: 1.10; 95% CI: 0.75 to 1.62) of death, MI, anderebrovascular events. The rates of TVR were indeed signif-
cantly higher in the group that received stents than in the
roup that underwent CABG (HR: 4.76; 95% CI: 2.80 to
.11). Similar results were observed between patients that
eceived bare-metal stent versus CABG (Wave #1) and pa-
ients that received DES versus CABG (Wave #2).
In the SYNTAX trial, patients were stratified according
o the presence of ULMCA disease (15). The SYNTAX
rial enrolled and randomized 705 patients with ULMCA
esions: 348 in the CABG group versus 357 in the PCI
roup. The primary end point of noninferiority in 12-
onth rate of MACCE was met in PCI group (13.7% and
5.8%, respectively; p  0.44). Moreover, although the rate
f repeat revascularization among patients with ULMCA
isease was significantly higher in the PCI group (11.8% vs.
.5% in the CABG group; p  0.02), this result was offset
y a significantly higher rate of stroke in the CABG
ubgroup (2.7% vs. 0.3% in the corresponding PCI sub-
roup; p  0.01). Despite the encouraging results, it is
mportant to point out that even if ULMCA subanalysis
as pre-specified, the results should be taken as hypothesis
enerating because of the lack of adequate statistical power
nd needs to be tested in larger, adequately powered
andomized trials.
In our study, because of the nonrandomized nature, an
djusted analysis using the propensity score was performed
o take into account differences in baseline clinical charac-
Figure 2. MACCE at 5 Years
The ﬁgure shows there is no difference in the occurrence of major adverse
cardiac and cerebrovascular events (MACCE) in percutaneous coronary
intervention with drug-eluting stent as compared to coronary artery bypass
graft at 5-year clinical follow-up. No difference was present in the overall
population and according to quartiles at propensity score analysis. Abbrevi-
ations as in Figure 1.
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600eristics between the study groups. Still no difference was
bserved at a median of 61.9 months (IQR: 57.8 to 67.2
onths) in the occurrence of MACCE between elective
CI with DES implantation and CABG for unprotected
LMCA disease (32.4% vs. 38.3%, respectively) both for
he unadjusted (OR: 1.41; 95% CI: 0.79 to 2.51; p  0.26)
nd adjusted analysis (OR: 1.57; 95% CI: 0.82 to 3.05; p 
.18). Interestingly, our study also confirmed that the
enefit of PCI over CABG in reducing the composite end
oint of cardiac death, MI, and cerebrovascular events
bserved at 1 year (16) was sustained at 5 years (20.4% in the
ABG group vs. 11.2% in the PCI group; unadjusted OR:
.38; CI 95%: 0.16 to 0.86; p  0.02; adjusted OR: 0.43;
5% CI: 0.17 to 0.97; p  0.04).
Conversely, the advantage of CABG in reducing the need
or repeated revascularization was once again confirmed.
he lower need for revascularization in CABG suggests
hat at least “first-generation” DES (exclusively used in this
reliminary phase of our experience from 2002 to 2004) are
till an imperfect solution that are unable to completely
liminate restenosis in complex settings such as bifurca-
ional lesions and multivessel disease. However, it might be
air to point out that routine angiographic follow-up was
art of this initial protocol to detect early left main stent
estenosis and that many TLR were angiographically rather
han clinically driven. Angiographic follow-up was per-
ormed in 96 (89.7%) of the patients; 95% of restenosis
ccurred in patients with treatment of distal ULMCA and
ere focal. The low rate of intravascular ultrasound guid-
nce (28.9%) as well as the more generous use of stents
ithout a properly sized post-dilation could clearly have
layed an important role in the occurrence of TLR in PCI
roup. Interestingly, there were 3 new TLR in the PCI and
in the CABG groups from 1 to 5 years, which suggests
hat at least in this preliminary experience, a late catch-up
henomenon was not observed.
From a safety perspective, the cardiac death rates (11.9%
n CABG vs. 7.5% in PCI) reported at 61.9 months (IQR:
7.8 to 67.2) clinical follow-up are quite reassuring consid-
ring the risk profile of the patients included in the analysis
EuroSCORE 6 in approximately 30% of the patients)
Table 1). Interestingly, in the CABG group, 2.8% (n  4)
ad a symptomatic graft occlusion versus 0.93% (n  1) of
efinite and/or probable ST (only 1 definite ST and no
robable ST). The only definite ST was a late ST in a
aclitaxel-eluting stent implanted in the proximal left ante-
ior descending artery at 3.9 months while on DAT. The
atient experienced an acute anterior MI successfully treated
ith re-PCI. Possible ST at 5-year follow-up was adjudi-
ated in 6 patients (5.6%), 4 out of 6 had a left ventricular
jection fraction 35%, and all of them had a distal left
ain true bifurcation lesion (Table 3). Notably, only 34% of
he patients in PCI group were on long-term DAT at the
ime of last clinical follow-up.Considering these encouraging long-term results and the
echnical development in PCI (second-generation DES,
igher use of intravascular ultrasound and fractional flow
eserve, new imaging techniques such as optimal coherence
omography, and assessment of clopidogrel responsiveness)
s well as in CABG (higher percentage of off-pump-no-
ouch technique), there is now a clear need for a prospective,
andomized trial adequately powered to detect a difference
n the composite end point of cardiac death, MI, and CVA
t 5-year clinical follow-up to evaluate the optimal revascu-
arization treatment in unprotected ULMCA lesions. Ques-
ions remain unanswered regarding the need to include
evascularization in the primary end point and the exclusion
f patients with extensive triple-vessel disease, in addition to
eft main stenosis.
tudy limitations. The major limitation is that this is an
bservational and not a randomized study. This limit was
ainly due to the exploratory nature of the study. Although
he small number of patients enrolled in the present study
epresents an important limitation, we nevertheless per-
ormed a propensity score adjustment to reduce the disad-
antage caused by the higher-risk profile of the patients
reated with CABG. Moreover, despite the numerical
ifference, the small sample size allows us to detect as
tatistically significant only very large differences in mortal-
ty rates between the 2 study groups.
Another limit of the study was the fact that in CABG
roup, because of the retrospective nature of the study, we
ould not analyze all the baseline angiograms in order to
alculate SYNTAX score as also reported in Table 1.
onclusions
n this single-center observational experience, there was still
o difference in the occurrence of MACCE between elec-
ive PCI with DES implantation and CABG in ULMCA
esions, at a median clinical follow-up of 61.9 months (IQR:
7.8 to 67.2 months). This study confirmed a possible
dvantage of PCI in the composite end point of death, MI,
nd/or stroke, whereas a benefit in reducing the need for
epeated revascularization was still observed in CABG.
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